Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA 02115, USA.
J Clin Oncol. 2011 Jul 1;29(19):2619-27. doi: 10.1200/JCO.2010.29.5907. Epub 2011 May 23.
Traditionally, larger tumor size and increasing lymph node (LN) involvement have been considered independent predictors of increased breast cancer-specific mortality (BCSM). We sought to characterize the interaction between tumor size and LN involvement in determination of BCSM. In particular, we evaluated whether very small tumor size may predict for increased BCSM relative to larger tumors in patients with extensive LN involvement.
Using Surveillance, Epidemiology and End Results registry data, we identified 50,949 female patients diagnosed between 1990 and 2002 with nonmetastatic T1/T2 invasive breast cancer treated with surgery and axillary LN dissection. Primary study variables were tumor size, degree of LN involvement, and their corresponding interaction term. Kaplan-Meier methods, adjusted Cox proportional hazards models with interaction terms, and a linear trend test across nodal categories were performed.
Median follow-up was 99 months. In multivariable analysis, there was significant interaction between tumor size and LN involvement (P < .001). Using T1aN0 as reference, T1aN2+ conferred significantly higher BCSM compared with T1bN2+ (hazard ratio [HR], 20.66 v 12.53; P = .02). A similar pattern was seen among estrogen receptor (ER) -negative patients with T1aN2+ compared with T1bN2+ (HR, 24.16 v 12.67; P = .03), but not ER-positive patients (P = .52). The effect of very small tumor size on BCSM was intermediate among N1 cancers, between that of N0 and N2+ cancers.
Very small tumors with four positive LNs may predict for higher BCSM compared with larger tumors. In extensive node-positive disease, very small tumor size may be a surrogate for biologically aggressive disease. These results should be validated in future database studies.
传统上,较大的肿瘤大小和淋巴结(LN)受累程度增加被认为是乳腺癌特异性死亡率(BCSM)增加的独立预测因素。我们试图描述肿瘤大小和 LN 受累程度之间的相互作用,以确定 BCSM。特别是,我们评估了在广泛 LN 受累的患者中,非常小的肿瘤大小相对于较大的肿瘤是否可以预测 BCSM 增加。
使用监测、流行病学和最终结果(SEER)登记处的数据,我们确定了 50949 名在 1990 年至 2002 年期间诊断为非转移性 T1/T2 浸润性乳腺癌的女性患者,这些患者接受了手术和腋窝淋巴结清扫术治疗。主要研究变量是肿瘤大小、LN 受累程度及其相应的交互项。进行了 Kaplan-Meier 方法、具有交互项的调整 Cox 比例风险模型和线性趋势检验。
中位随访时间为 99 个月。在多变量分析中,肿瘤大小和 LN 受累之间存在显著的相互作用(P <.001)。使用 T1aN0 作为参考,T1aN2+ 与 T1bN2+相比,BCSM 显著更高(风险比 [HR],20.66 v 12.53;P =.02)。在雌激素受体(ER)阴性患者中也观察到类似的模式,T1aN2+与 T1bN2+相比,BCSM 更高(HR,24.16 v 12.67;P =.03),但在 ER 阳性患者中则不然(P =.52)。在 N1 癌症中,非常小的肿瘤大小对 BCSM 的影响处于 N0 和 N2+癌症之间。
与较大的肿瘤相比,有四个阳性淋巴结的非常小的肿瘤可能预示着更高的 BCSM。在广泛的淋巴结阳性疾病中,非常小的肿瘤大小可能是生物学侵袭性疾病的替代指标。这些结果应在未来的数据库研究中得到验证。